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Abstract 
Background: The underlying etiology of recurrent aphthous stomatitis (RAS) is unclear and treatment aims to pro-
vide symptomatic and faster relief. This study compared the efficacy of diode laser, a herbal combination of Acacia 
nilotica and Licorice (A and L) and Amlexanox in the management of RAS.
Material and Methods: Sixty patients with minor aphthae were selected and randomly divided into four groups of 
15 each. Group I and II received adhesive preparations of a herbal mixture of A and L and a 2 mg Amlexanox paste 
respectively, group III received diode laser and the fourth group (control) used a placebo. Ulcer size, pain score 
were recorded on days 1, 2 and 5. 
Results: Laser group showed the statistically highest mean percentage (%) of reduction in pain scores and ulcer 
size than the other groups.  The mean % of reduction in pain scores was 43.3+20.0 at day 2 and 67.8+21.5 % at 
day 5 in the laser group while Amlexanox group demonstrated a 29.8 +11.3 and 61.9+24.5 mean % of reduction 
in pain scores at day 2 and 5 respectively. A and L group showed a lower mean % of reduction in pain scores than 
laser and Amlexanox groups with a 22.2+10.5 and 43.4+15.8 mean % reduction in pain scores at day 2 and day 5 
respectively. Similarly the highest mean % of reduction in ulcer size was seen in the laser group being 52.7+19.8 at 
day 2 and 85.1+22.0 at day 5, while it was 48.1+16.5 at day 2 and 77.8+28.7 at day 5 in the Amlexanox group and 
42.0+11.5 at day 2 and 63.0+20.5 at day 5 in the A and L group.   
Conclusions: All treatment modalities reduced pain and ulcer size than placebo group. Laser therapy demonstrated 
the highest percentage of reduction of pain score and ulcer size.
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Introduction
Recurrent aphthous stomatitis (RAS) is the most com-
mon ulcerative disease of the oral mucosa affecting as 
high as 15-25 % of the general population worldwide 
(1). It is a multifactorial disease and several predisposing 
and risk factors have been implicated in its pathogene-
sis. Due to uncertain etiology and unpredictable course 
of the disease, there is no definitive treatment for RAS 
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(2). Treatment strategies therefore aim at relieving pain, 
promoting healing and preventing secondary infection 
(3). In severe forms of RAS, systemic agents such as 
colchicine, dapsone and corticosteroids may be adminis-
tered to control the symptoms. However most of these 
therapies are associated with side-effects or unwanted 
reactions (4). Several topical agents are available for 
symptom relief in less severe forms of RAS. These in-
clude antibacterial, anti-inflammatory, anti-histaminic 
agents, as well as analgesics, local anesthetics and glu-
cocorticoids (5,6).
Amlexanox 5%, a topical anti-inflammatory and anti-
allergic drug was found to play a significant role in the 
management of minor aphthous ulcers. Amlexanox po-
tentially inhibits the formation and release of histamine 
and leukotrienes from mast cells, neutrophils, and mo-
nonuclear cells. It has been shown to accelerate healing 
of aphthae and decrease pain, erythema and size of the 
lesion (7,8). Amlexanox oral paste has been specifically 
formulated to adhere to the oral mucosa, thus limiting 
the likelihood of the drug being rubbed or rinsed away 
with saliva.
On the other hand laser therapy constitutes an alternati-
ve therapy to oral diseases that present   with pain and 
inflammatory reactions and that require tissue regene-
ration, since a laser provides better anti-inflammatory 
responses with edema reduction, pain reduction and ce-
llular bio-stimulation (9). Apart from RAS, Low level 
laser therapy (LLLT) has been used in treatment of other 
mucosal ulcers as lichen planus, pemphigus vulgaris, 
mucous membrane pemphigoid, etc... However despite 
publishing a large number of studies about LLLT in oral 
ulcers, treatment protocols have been conflicting (10).
The use of natural products, including medicinal plant 
preparations for pain reduction and shortening of hea-
ling time of oral aphthous ulcers are gaining more at-
tention due to their decreased side effects and drug re-
sistance (2).
Acacia nilotica (A), commonly known as Indian gum 
Arabic tree is rich in flavonoids,  simple phenolics, sapo-
nins, quinines,  tannins, coumarins and polysaccharides 
(11) and is used in the treatment of many diseases In In-
dia and Africa it is customarily for treating cancers, and 
the plant has been also reported to be used in treatment 
of dental pain (12-14). Extracts of A was found to exhi-
bit an antifungal property against candida albicans and 
also inhibited S. mutans (15). A was found to be the most 
active plant against bacteria as well as fungal pathogens 
when compared with other medicinal plants (16). 
Licorice (L), the name given to the roots and stolons of 
Glycyrrhiza species, has been used since ancient times 
as a traditional herbal remedy (17). L contains several 
classes of secondary metabolites that have numerous hu-
man health benefits and many studies have demonstra-
ted both licorice and its bioactive ingredients to possess 
potential beneficial effects in several oral diseases which 
are attributed mainly to the anti-adherence and anti-in-
flammatory properties of the L compounds (18,19). L 
used in treating gastric ulcers increased blood supply 
and mucous secretion thus aiding the healing of ulcera-
ted mucosa (20). 
Medicinal plants have a great capability for displaying 
a synergistic action owing to their multi-component na-
ture (21). Hence combination of both the antibacterial 
effect of A and the anti-inflammatory effect of L extracts 
may present a probable synergism that might accelerate 
the healing of RAS.
The aim of this study was therefore to compare the effi-
cacy of three different treatment modalities:  diode laser, 
a herbal combination of A and L and Amlexanox in the 
management of RAS.
Material and Methods
-Plant material
Dried roots and rhizomes of Glycyrrhiza glabra L., Fa-
mily Leguminosae and pods of Acacia nilotica Lwill-
dFamily Leguminosae were purchased from a local 
market in Cairo, Egypt and authenticated by Dr. Abdel 
Haleem AbdelMotagaly, Dept. of Flora, the Agricultural 
Museum, Dokki, Giza, Egypt. The plants were crushed 
and grinded into suitable size for phytochemical study.
-Preparation of biologically active fractions and identifi-
cations of compounds
Extraction, isolation and identification of the natural com-
pounds from the two plants were carried out separately 
A. nilotica and Glycyrrhiza glabra were extracted separa-
tely using solvents of increasing polarity in the following 
order: petroleumether, ether, chloroform, methanol, and 
water. These extracts were evaporated to dryness under 
vacuum at 40°C, lyophilized, and saved for pharmaceuti-
cal preparation. The collected polar extracts were subjec-
ted to phytochemical investigation using different chro-
matographic and spectral procedures as; PC, CC, TLC, 
Preparative HPLC, LC/MS, High field NMR, 1H-NMR, 
13C-NMR,HMBC, HMQC, H1H1-COSY, and ESI-MS. 
-Preparation of Herbal Adhesive Paste
The adhesive paste was dispensed containing both A 
and L dry extracts, each at 1% composition forming a 
total of 2% of the herbal paste. Gelatin, Polyethylene 
glycol 20000, glycerine, Polyethylene glycol 400, her-
bal extracts. Tween 20 and distilled water were mixed 
after weighing appropriate amounts and heated at 70°C 
till complete dissolution of the components. Similarly, 
sodium carboxy methyl cellulose and pectin were dis-
persed in liquid paraffin, mixed well and heated at 70°C. 
The oily portion was then poured on the aqueous portion 
with continuous stirring at 70°C till complete homoge-
neous blending. The formulation was removed from the 
hot plate and left to cool to room temperature before 
application by patients for treatment of dental lesions.
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-Patients and Methods:
A total of 60 patients, females (62%) and males (38%) 
with mean age 28.5 years (19-40 years) and a current his-
tory of RAS were recruited from the outpatient clinic of 
Oral Medicine and Periodontology, Oral Diagnosis and 
Radiology department, Faculty of Dentistry, Ain Shams 
University. The study has been carried out in accordance 
with The Code of Ethics of the World Medical Associa-
tion (Declaration of Helsinki) for experiments involving 
humans. Before entering the study, eligible subjects were 
informed regarding the purpose of this study and provided 
a signed consent to participate in this study. The protocol 
was approved by Ein Shams University’s Ethical Com-
mittee. Inclusion criteria included subjects with a history 
of at least two confirmed episodes of RAS during a 3-6 
months untreated baseline period. Exclusion criteria in-
cluded pregnant females, smokers or those suffering from 
psychological disturbances, inflammatory and allergic 
conditions, or those with special syndrome where RAS is 
one of its symptoms (e.g. Behcet’s syndrome); those with 
aphthous lesions older than 4 days, and patients that have 
received any other treatment for the last 4 weeks.
-Study design
Subjects satisfying the inclusion criteria were assigned 
randomly to one of the four-treatment groups: group I 
received adhesive pastes of A and L, group II received 
adhesive oral tablets of 2mg Amlexanox *, group III 
received diode laser irradiation and group IV assigned 
as the control group received a placebo adhesive tablet. 
Patients of group I, II and IV were instructed to apply 
the medication on the lesion q.i.d. after drying it with a 
small sterile cotton pad and refrain from eating at least 
for 30 min after the drug application. Treatment conti-
nued till for 5 days. A 970 nm diode lasers was used for 
the treatment of RAS in a non-contact mode. A 320 mi-
cron fiber optic tip diameter was used to deliver the laser 
beam; the initiation was done on an articulating paper. 
Then diode Siro laser ** was started at a de-focused mode 
from the lesion (5-8 mm) and advanced slowly towards 
the area ending up 2-3mm away and continuously mo-
ving from the periphery of the lesion to the center “pain-
ting “ the entire area and moving away from the lesion if 
the patient feels warmth. The setting was put at 0.8w for 
30-45 seconds with a refractory period of 15-20 seconds 
between laser “passes” to allow for tissue relaxation. The 
area was rubbed gently with a wet gloved finger to deter-
mine if a decrease in pain was felt by the patient. A 2nd 
or a 3rd laser pass was occasionally needed to decrease 
the pain with a maximum time of three minutes total irra-
diation time. The laser treatment consisted of one sitting 
which started at day 0. Each sitting consisted of a maxi-
mum of four sessions of applications. 
*Aphthatab, EVA pharma,. Cairo, Egypt.
 **970nm SIRO Laser Advance class IIIb, SIRONA The 
Dental company, Germany.
After each pass, the area was checked with palpation. 
The patients were asked to refrain from using any medi-
cations over the next 5 days. The pain scores and sizes of 
the ulcers were evaluated on treatment days 0, 2 and 5. 
Pain was recorded using the visual analog scale (VAS), 
from 1-10 with 10 being most severe, and subjects were 
instructed to mark the number representing their level of 
perceived pain. The size of the ulcer was measured by 
a single oral specialist who was blinded to the subject’s 
status using a William’s graduated periodontal probe.
-Statistical analysis
Numerical data were explored for normality by checking 
the distribution of data, calculating the mean and median 
values as well as using tests of normality (Kolmogorov-
Smirnov and Shapiro-Wilk tests). All data showed non-
parametric distribution. Data were presented as mean and 
standard deviation (SD) values. Kruskal-Wallis test was 
used to compare between the four groups. Mann-Whitney 
U test was used to for pair-wise comparisons when Krus-
kal-Wallis test is significant. Bonferroni’s correction was 
applied for the pair-wise comparisons.The significance le-
vel was set at P ≤ 0.05. Statistical analysis was performed 
with IBM® SPSS® Statistics Version 20 for Windows.
Results
-Pain score
At day 2, and 5 control group showed the statistically 
significantly highest mean pain score which was (9.3 
+0.5) at day 2 and 9.1+0.7 at day 5. No statistically 
significant difference was observed between the three 
treatment groups at day 2.  (p=0.010), where  mean pain 
scores were 7.7+1.1, 5.9+1.1, and 5.1+1.2 for A and L, 
Amlexanox and Laser groups respectively. At day 5 both 
Amlexanox and Laser groups demonstrated statistically 
significantly lower mean pain scores than A and L group 
(p < 0.001), where the mean pain score results for the 
Amlexanox group was 3.2+1.6 and for the laser group 
2.9 +1.1 while that of A and L group was 5.6+1.3 (Table 
1, Fig. 1A).
-Ulcer size
Similar to the pain score, control group showed the sta-
tistically significantly highest mean ulcer size in both 
days 2 and 5 with a mean ulcer size of 6.5+1.0 at day 
2 and 6.3+1.1 at day 5. Statistical results demonstra-
ted no statistical difference between all three treatment 
modalities at day 2; where the mean ulcer size recorded 
4.7+1.2, 4.2+1.3 and 3.5+1.2 for A and L, Amlexanox 
and Laser groups respectively.  At day 5, A and L group 
showed statistically significantly lower mean ulcer size 
than the control group (p<0.001), while Amlexanox and 
Laser groups; both showed the lowest mean ulcer sizes 
with no statistically significant difference between them. 
The mean ulcer size was 3.0+0.7, 1.8+0.6 and 1.1+0.3 
for A and L, Amlexanox and Laser groups respectively 
(Table 1, Fig. 1B).
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Group
Variable
Aand L Amlexanox Laser Control P-Value
Pain Score Day 0 9.9 ± 0.4 8.4 ± 1.8 9.0 ± 1.1 9.7 ± 0.5 0.785
Day 2 7.7 ± 1.1  b 5.9 ± 1.1 b 5.1 ± 1.2 b 9.3 ± 0.5 a 0.010 *
Day 5 5.6 ± 1.3 b 3.2 ± 1.6 c 2.9 ± 1.1 c 9.1 ± 0.7 a <0.001*
% reduction
Day 2
22.2 ± 10.5 b 29.8 ± 11.3 b 43.3 ± 20.0 a 4.1 ± 0.5 c <0.001*
% reduction
Day 5
43.4 ± 15.8 b 61.9 ± 24.5 a 67.8 ± 21.5 a 6.2 ± 1.6 c <0.001*
Ulcer Size 
(mm)
Day 0 8.1 ± 1.3 8.1 ± 1.6 7.4 ± 1.9 7.0 ± 1.3 0.257
Day 2 4.7 ± 1.2 b 4.2 ± 1.3 b 3.5 ± 1.2 b 6.5 ± 1.0 a <0.001*
Day 5 3.0 ± 0.7 b 1.8 ± 0.6 c 1.1 ± 0.3 c 6.3 ± 1.1 a <0.001*
% reduction
Day 2
42.0 ± 11.5 b 48.1 ± 16.5 a 52.7 ± 19.8 a 7.1 ± 5.3 c <0.001*
% reduction
Day 5
63.0 ± 20.5 b 77.8 ± 28.7 a 85.1 ± 22.0 a 10.0 ± 7.3 c <0.001*
Table 1. Mean ± standard deviation (SD) values and results of comparison between different parameters in the four groups.
*: Significant at P ≤ 0.05, Different superscripts in the same row are statistically significantly different.
Fig. 1. A,B) Mean pain score and mean ulcer size before and after 
treatment in the four groups.
Regarding the percentage of reduction, Laser group 
showed the statistically significantly highest mean per-
centage (%) of reduction in pain scores and ulcer size 
than the other groups.  The mean % of reduction in pain 
scores was  43.3+20.0  (at day 2) and 67.8+21.5 % (at 
day 5) in the laser group  in comparison to Amlexanox 
group which demonstrated  a 29.8+11.3 and 61.9+24.5 
mean % of reduction in pain scores at day 2 and 5 res-
pectively.  A and L group showed a lower mean % of re-
duction in pain scores than laser and Amlexanox groups 
with a 22.2+10.5 and 43.4+15.8 mean % reduction in 
pain scores at day 2 and day 5 respectively. Similarly the 
highest mean % of reduction in ulcer size was seen in 
the laser group being 52.7+19.8 at day 2 and 85.1+22.0 
at day 5, while it was 48.1+16.5 at day 2 and 77.8+28.7 
at day 5 in the Amlexanox group and 42.0+11.5 at day 2 
and 63.0+20.5 at day 5 in the A and L group. The control 
group showed the statistically significantly lowest mean 
% reduction in pain and ulcer size scores (Table 1, Figs. 
2 A,B).
Discussion
The multifactorial etiology of RAS and lack of effective 
treatment modality makes the therapeutic aim  to pro-
vide symptomatic relief for the patient, aiming mainly 
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Fig. 2. A,B) Mean % of reduction in pain score and ulcer size after 
treatment in the four groups.
at decreasing pain, size, and number of ulcers (22). Not 
all treatment modalities are successful in achieving all 
these goals, and therefore it is important to evaluate any 
clinical trial to determine if a medication should be re-
commended for widespread use (1).
In the present study a comparison between the effica-
cies of diode laser, a mixture of A and L, Amlexanox 
on reduction of pain and lesion size in RAS was perfor-
med. The frequency of recurrence was not investigated 
in our study. Although some treatments were successful 
in reducing the frequency of recurrence in RAS, no stu-
dy could come into agreement with respect to reducing 
the recurrence rate of aphthous ulcers (23). No routine 
laboratory procedures were necessary since history and 
clinical examination of the lesions were characteristic of 
RAS (24).
The reason behind choosing diode laser counterparts is 
the many advantageous this type has over high powered 
laser. Diode lasers do not cause thermal injury to the tis-
sues, are affordable, easy to use, with superior electrical 
and optical efficiencies (25). One W was used in this stu-
dy, because all tissues reactions in aphthous ulcerations 
occur in the epithelium negating the use of high power 
laser treatment. Using higher doses tend to decrease 
cellular proliferation thus slowing the healing process 
(26). A refractory period of 15-20 seconds between laser 
“passes” was allowed to give the chance for the tissue to 
cool down (27). 
When statistically comparing the pain and ulcer size 
between the groups, all three study group demonstrated 
reduction in pain and ulcer size than the control (pla-
cebo) group at all periods. The control group also de-
monstrated reduction in pain and ulcer size throughout 
the different study periods. This could be explained by 
the patients’ feeling of being treated giving them a sense 
of relief, or the placebo forming a film covering the ul-
cer thus providing a protective mechanical effect of the 
placebo possibly forming a film covering the ulcer and 
providing some soothing effect. It could be also due to 
the nature of the ulcer itself, being self-limiting (28).
Laser group demonstrated the lowest mean percentage 
of reduction in both pain scores and ulcer size at day 2 
and 5, with a statistically significant difference between 
laser group and both A and L and control group. The 
effect of Amlexanox on pain and ulcer size reduction 
was close to that of laser with no statistical significant 
difference observed between both groups except at day 2 
where laser demonstrated a statistically significant lower 
percentage of pain reduction denoting the faster effect of 
laser in alleviating pain in RAS patients.   
It was proposed that LLLT accelerates wound healing 
and reduces pain by stimulating collagen production, 
altering DNA synthesis and improving the function of 
neurological tissue. In two case reports LLLT provided 
instant pain relief and rapid decrease in ulcer size which 
is in accordance with the results of the present study (25). 
De Souza et al. (27) revealed reduction in pain in the 
same session after laser treatment and total regression 
of the lesion in 4 days in comparison to corticosteroid 
therapy where total regression occurred in 5-7 days.
Many studies demonstrated improvement in healing with 
reduction of pain, size, duration and recurrence of RAS 
when Amlexanox paste was applied. Authors attributed 
this effect to Amlexanox causing inhibition of release of 
histamines and leukotrienes from mast cells and neutro-
phils and the release of inflammatory cytokine IL-1 beta, 
thus increasing the vascular permeability and aiding in 
the healing of the ulcer (8,24). Since Amlexanox oral 
paste is easily available and affordable, easy to carry and 
demonstrated no significant unfavorable taste, some pa-
tients might prefer it over laser which requires a more 
precise and lengthy procedure. 
In the present study, the group using A and L demons-
trated better results than the placebo group, however the 
percentage of reduction in both pain scores and ulcer 
size in the A and L group was less than that of the laser 
and Amlexanox groups. The use of herbal extracts either 
individually or in a combination of more than one extract 
has shown to be effective in treating many diseases in-
cluding oral ulcers (15), which is in accordance with the 
results of the present study. However while some studies 
using natural medications in RAS treatment demons-
trated significant improvement in pain, and reduction 
of ulcer size and duration of ulcers other results proved 
insignificant when the efficacy of herbal medication  on 
ulcer size and healing time was compared with placebo 
results (28,29).
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It can therefore be concluded that all three treatment mo-
dalities reduced pain and ulcer size in comparison with 
placebo group, however RAS treatment using diode la-
ser demonstrated the highest percentage of reduction in 
pain scores and ulcer size. Thus it is safe to assume that 
the choice of treatment modality might depend on the 
case itself. Since aphthous ulcers are recurrent, studies 
on a larger no of subjects and for a longer term may be 
needed for more beneficial results.
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